Risk of cervical cancer after HPV detection in healthy women

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a population-based, retrospective observational study using existing health registries in the Stockholm region. It examines incident, persistent, and history-unknown HPV detections by genotype to estimate short- and longer-term cancer risk. The analysis uses data from 2014–2023 when primary HPV screening was used, including women aged 22–70. No participants are contacted or required to perform tasks; data are drawn from routine screening records. The goal is to inform whether particular HPV findings require immediate clinical action or can wait until the next screening.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Women living in the Great Stockholm Region in Sweden, at cervical screening ages (age 22-70 years), and having had an HPV positive result in primary HPV test during 2014-2023

Exclusion Criteria:

* Women without valid personal identity number in the population registry

Where it's running

• Centre for Cervical Cancer Elimination, Department of Clinical Science, Intervention and Technology, Karolinska Institutet
  Stockholm, Sweden Recruiting

Study contacts

• Study coordinator: Jiangrong Wang, PhD
• Email: jiangrong.wang@ki.se
• Phone: +46769309451

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Q-Pad menstrual-pad test to detect high-risk HPV and cervical precancer

  This study tests whether a home menstrual-pad kit (Q-Pad) can detect high-risk HPV and cervical precancer in people referred for colposcopy after an abnormal Pap or HPV result.

  Recruiting at 3 sites Qurasense · New Haven, Connecticut and 2 other locations · NCT07281599

• Routine shallow-coverage Whole Genome Sequencing of Cervical Smears to See if Ovarian Cancer is Found Earlier

  Researchers test whether analyzing DNA from cervical smears with shallow whole-genome sequencing can help detect high-grade serous ovarian cancer early in patients undergoing treatment for this cancer.

  Recruiting Institut Claudius Regaud · Toulouse · NCT07821879

• HPV self-sampling in the ED to screen under-screened women

  This study tests whether giving an HPV self-sampling kit in the emergency department can help under-screened women get screened for cervical cancer and find those with HPV to guide follow-up care.

  Recruiting Rutgers, The State University of New Jersey · New Brunswick, New Jersey and 1 other locations · NCT07657104

• Dysplasix™ intravaginal suppositories for women with high‑risk HPV and mild cervical cell changes

  This trial tests whether nightly Dysplasix™ vaginal suppositories can clear high‑risk HPV and help mild cervical cell changes (ASC‑US or LSIL) in adult women.

  Recruiting Phase 2 Amplexd Therapeutics, Inc. · Shatin, New Territories · NCT07572396

• Low-cost HPV test that gives same-day results and treatment in women 30-59

  A low-cost HPV test done on the same day as a self-collected sample is being tested to see if it can reliably screen for cervical cancer and enable immediate treatment in women aged 30-59 in San Salvador.

  Recruiting The Cleveland Clinic · San Salvador, Oriente · NCT07538050

• At-home HPV self-collection kits for cervical cancer screening

  We are testing different ways to give at-home HPV self-collection kits to under-screened people aged 25–65 to see if more of them complete cervical cancer screening and follow-up.

  Recruiting Washington University School of Medicine · St Louis, Missouri · NCT07453459

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.